Stockscreener 앱 받기
2.82
2.08%
-0.06
시간 외 거래:
2.83
0.01
+0.35%
Incannex Healthcare Inc 주식(IXHL)의 최신 뉴스
Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight - The Manila Times
Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight - GlobeNewswire Inc.
Kairos Pharma, Ltd. (KAPA) Stock Price & News - Syfe
Why Did Incannex (NASDAQ:IXHL) Dose Its First Sleep-Apnea Patient? - Kalkine Media
Incannex begins Phase 2 dosing study for sleep apnea drug By Investing.com - Investing.com South Africa
Incannex begins Phase 2 dosing study for sleep apnea drug By Investing.com - Investing.com Nigeria
$Incannex Healthcare (IXHL.US)$ - Moomoo
Incannex Begins Dosing in Phase 2 Sleep Apnea Trial - minichart.com.sg
Incannex begins Phase 2 dosing study for sleep apnea drug - Investing.com
Incannex begins Phase 2 dosing study for sleep apnea drug By Investing.com - Investing.com Canada
A company with about $70 million in cash and no debt is testing a sleep-apnea treatment. - Stock Titan
IXHLIncannex Healthcare Inc Revenue Breakdown - Finviz
BB: BlackBerry Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Enterprise value to EBIT forward of Incannex Healthcare Limited – LSX:A2DF4D - TradingView
IXHL Q4'26 Earnings: EPS estimate is (0.14) USD - TradingView
Incannex Healthcare (IXHL) Slides 4.97% to $3.46, Testing Support at $3.29ETF Premium Discount - vinanet.vn
Incannex Healthcare (IXHL) Slides 4.97% to $3.46, Testing Support at $3.29Change of Character - dars.gov.et
What’s Next for Incannex Healthcare (ASX:IHL) After US Patent Win? - Kalkine Media
IXHL Q4'26 Earnings: revenue estimate is 0 USD - TradingView
Incannex doses first patient in sleep apnea drug trial By Investing.com - Investing.com Nigeria
Incannex doses first patient in sleep apnea drug trial - Investing.com India
Incannex (IXHL) Advances Sleep Apnea Drug Trial Amid High Price-to-Sales Valuation - GuruFocus
Incannex Healthcare Doses First Patient in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea - Quiver Quantitative
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X - Barchart.com
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X - The Manila Times
Incannex Healthcare (ASX:IHL) Cash Flow Check: What Investors Need to Watch on 19 August - Kalkine Media
Why Is Incannex Healthcare (ASX:IHL) in Market Focus? - Kalkine Media
Incannex Wins US Patent Lift For Sleep Apnoea Pipeline (ASX:IHL) - Kalkine Media
Incannex Healthcare (IXHL) Shows Modest Uptick, Holding Key Support Amid Clinical Pipeline FocusTrend Continuation Trade - vinanet.vn
Incannex Healthcare (IXHL) Climbs 3.8% to $3.28, Testing Key Resistance ZoneMcClellan Summation - vinanet.vn
Incannex Healthcare (IXHL) Climbs 3.8% to $3.28, Testing Key Resistance ZoneGap and Reverse - dars.gov.et
Incannex Healthcare (IXHL) Shows Modest Uptick, Holding Key Support Amid Clinical Pipeline FocusVolatility Skew - dars.gov.et
Polar Asset Management (IXHL) reports 7.0% beneficial stake via 900,000 warrants - Stock Titan
$Incannex Healthcare (IXHL.US)$ - Moomoo
Incannex (ASX:IHL): What Is Changing in the Liquidity Test? - Kalkine Media
Why Does Incannex Healthcare (ASX:IHL) Shape Discipline? - Kalkine Media
Incannex Healthcare (ASX:IHL) Clinical Development Pipeline: Market Outlook - Kalkine Media
Incannex Healthcare Inc. (IXHL) options chain - Yahoo Finance Singapore
Incannex Secures A$5.1M R&D Tax Incentive Refund - theglobeandmail.com
Why Are Incannex Healthcare (ASX:IHL), Cann Group (ASX:CAN), ECS Botanics (ASX:ECS) and Little Green Pharma (ASX:LGP) Back in the Market Spotlight? - Kalkine Media
Why Are BrainChip (ASX:BRN), Incannex Healthcare (ASX:IHL), Lake Resources (ASX:LKE) and Cann Group (ASX:CAN) Back in the Market Spotlight? - Kalkine Media
Incannex receives final A$5.1m R&D tax incentive refund By Investing.com - Investing.com UK
$Incannex Healthcare (IXHL.US)$ - Moomoo
Incannex receives final A$5.1m R&D tax incentive refund By Investing.com - Investing.com Australia
Incannex receives final A$5.1m R&D tax incentive refund - Investing.com
Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 - The Manila Times
Form 8K Incannex Healthcare Inc. For: 11 August By Investing.com - Investing.com Nigeria
Form 8K Incannex Healthcare Inc. For: 11 August By Investing.com - Investing.com Australia
Form 8K Incannex Healthcare Inc. For: 11 August By Investing.com - Investing.com Canada
Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 - marketscreener.com
6.14%
1.49%
자본화:
|
볼륨(24시간):